Lonza Group Ltd – Strategy, SWOT and Corporate Finance Report

Lonza Group Ltd – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Lonza Group Ltd (Lonza) is a provider of contract manufacturing and development solutions to life-science industry. The company offers services including, commercial mammalian and microbial manufacturing, clinical development and manufacturing. It also offers high potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Scope

Detailed information on Lonza Group Ltd required for business and competitor intelligence needs

A study of the major internal and external factors affecting Lonza Group Ltd in the form of a SWOT analysis

An in-depth view of the business model of Lonza Group Ltd including a breakdown and examination of key business segments

News about Lonza Group Ltd, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Lonza Group Ltd and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Lonza Group Ltd as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Lonza Group Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Zep Inc.

Sannitree International

Royal DSM NV

NBE-Therapeutics AG

Mabuhay Vinyl Corp

Dottikon ES Holding AG

Caladrius Biosciences Inc

BASF SE

Aliancys AG

Actelion Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Lonza Group Ltd - Key Facts

Lonza Group Ltd - Key Employees

Lonza Group Ltd - Key Employee Biographies

Lonza Group Ltd - Key Operational Employees

Lonza Group Ltd - Major Products and Services

Lonza Group Ltd - History

Lonza Group Ltd - Company Statement

Lonza Group Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 Company Analysis

Company Overview

Lonza Group Ltd - Business Description

Business Segment: Pharma & Biotech

Overview

Performance

Business Segment: Specialty Ingredients

Overview

Performance

R&D Overview

Lonza Group Ltd - Corporate Strategy

Lonza Group Ltd - SWOT Analysis

SWOT Analysis - Overview

Lonza Group Ltd - Strengths

Lonza Group Ltd - Weaknesses

Lonza Group Ltd - Opportunities

Lonza Group Ltd - Threats

Lonza Group Ltd - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Lonza Group Ltd, Recent Deals Summary

Section 5 Company’s Recent Developments

Feb 13, 2019: Emerald Health Pharmaceuticals and Lonza announce agreement for manufacturing of novel cannabinoid-derived drug candidate

Feb 11, 2019: Lonza’s new pooled donor suspension hepatocytes enable the next level of reliability, robustness and customizability

Jan 30, 2019: Lonza achieved another excellent full-year result in 2018 with 9% organic sales growth and strong profitability driven by healthcare businesses

Jan 30, 2019: Lonza announces succession of CEO

Jan 15, 2019: Lonza announces retirement of Fridtjof Helemann

Jan 08, 2019: The world’s first fully automated plate-based robotic solution for high precision in endotoxin detection

Dec 10, 2018: Lonza to establish Strategic Biomanufacturing base in China using GE Healthcare Solution

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Lonza Group Ltd, Key Facts

Lonza Group Ltd, Key Employees

Lonza Group Ltd, Key Employee Biographies

Lonza Group Ltd, Key Operational Employees

Lonza Group Ltd, Major Products and Services

Lonza Group Ltd, History

Lonza Group Ltd, Subsidiaries

Lonza Group Ltd, Joint Venture

Lonza Group Ltd, Key Competitors

Lonza Group Ltd, Annual Ratios

Lonza Group Ltd, Annual Ratios (Cont…1)

Lonza Group Ltd, Annual Ratios (Cont…2)

Lonza Group Ltd, Interim Ratios

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Lonza Group Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Lonza Group Ltd, Performance Chart (2014 – 2018)

Lonza Group Ltd, Ratio Charts

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports